IMMU — Mendus AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK346.22m
- SEK304.26m
Brief: Mendus Reports Positive Read-Out For First Stage Vital-Cml Trial
Brief: Mendus Q2 Loss For Period At SEK 21.4 Million
Sweden's Mendus Q2 net loss narrows
Brief: Mendus Q2 Adjusted EPS SEK -0.34
Brief: Mendus Signs Agreement With South Australian Health and Medical Research Institute
Brief: Mendus Repurchases Outstanding Warrants From Fenja
Brief: Mendus Reports Positive Phase 1B Alison Trial Results In Hgsoc At Asco 2026
Brief: Mendus Says Vididencel Combination Potential Confirmed
Sweden's Mendus Q1 net loss narrows
Brief: Mendus Q1 Operating Profit SEK -20.095 Million
Brief: Mendus Receives All Regulatory Approvals For Vital-CML Study In CML
Brief: Mendus Announces Agreement With Olivia Newton-John Cancer Research Institute
Sweden's Mendus reports wider Q4 net loss, no revenue
Brief: Mendus Q4 Operating Profit SEK -38.706 Million
Brief: Mendus CEO Bought SEK 1.0 Mln Of Co Shares
Brief: Mendus AB Announces Positive 2-Year Follow-Up Data From Alison Trial
Brief: Mendus Raises SEK 52.5 Million Through Directed Share Issue
Brief: Mendus Q3 Operating Profit SEK -20.434 Million
Brief: Mendus Announces Updated Clinical Strategy, Operational Focus